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ARTICLE
Clinical Study
Impact of depth of response on survival in patients treated with
cobimetinib ± vemurafenib: pooled analysis of BRIM-2,
BRIM-3, BRIM-7 and coBRIM
Karl D. Lewis1, James Larkin2, Antoni Ribas3, Keith T. Flaherty4, Grant A. McArthur5,6, Paolo A. Ascierto7, Brigitte Dréno8, Yibing Yan9,
Matthew Wongchenko9, Edward McKenna10, Qian Zhu9, Yong Mun9 and Axel Hauschild11
BACKGROUND: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with
BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.
METHODS: The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was
estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in
previously identified prognostic subgroups based on disease characteristics and gene signatures.
RESULTS: Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-
free survival (PFS) and overall survival (OS) when evaluated as continuous variables. Patients with the deepest responses had long-
lasting survival outcomes (median PFS: 14 months; OS: 32 months with vemurafenib; not estimable with cobimetinib plus
vemurafenib). Cobimetinib plus vemurafenib improved depth of response versus vemurafenib monotherapy regardless of other
prognostic factors, including gene signatures.
CONCLUSIONS: Greater depth of response was associated with improved survival, supporting its utility as a measure of treatment
efficacy in melanoma and further evaluation of its incorporation into existing prognostic models. Cobimetinib plus vemurafenib
improved outcomes across quartiles of response regardless of prognostic factors or gene signatures and provided durable survival
benefits in patients with deep responses.
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BACKGROUND
The introduction of small-molecule BRAF inhibitors has improved
progression-free (PFS) and overall survival (OS) for patients with
BRAFV600-mutated metastatic melanoma.1–3 However, resistance
to BRAF inhibitors due to reactivation of the mitogen-activated
protein kinase (MAPK) pathway through MEK signalling limits the
median duration of PFS to ~6 months.4,5 Combined BRAF and MEK
inhibition provides broader and more comprehensive inhibition of
the MAPK pathway than BRAF inhibition alone, and combination
therapy with cobimetinib (a MEK inhibitor) and vemurafenib (a
BRAF inhibitor) has demonstrated significant clinical benefit
compared with vemurafenib monotherapy.5,6 Combined BRAF-
and MEK-targeted therapy is now a standard of care in patients
with BRAFV600-mutated melanoma.
Responses to BRAF and/or MEK inhibition vary among patients,
and it would be useful to identify those who respond well to
targeted therapy. Post hoc analyses of pooled data from multiple
trials suggest that greater depth of response is associated with
better disease control and increased survival in patients with
haematologic7 and solid cancers.8,9 Depth of response is a more
personalised and granular measure of tumour response than
Response Evaluation Criteria in Solid Tumours (RECIST) categories
of response, which could be helpful in assessing the variation in
patient outcome following initiation of targeted therapy. The
question remains whether the individual patients who have the
greatest reduction in tumour burden (depth of response) are the
patients who have the greatest OS or PFS.9
In this exploratory analysis, we aimed to evaluate the association of
depth of tumour response with survival outcomes in two cohorts of
patients treated with vemurafenib monotherapy or cobimetinib plus
vemurafenib. Prognostic subgroups defined by particular disease
characteristics and gene expression signatures that affect survival
outcomes have been identified in patients with BRAFV600-mutated
metastatic melanoma treated with BRAF and MEK inhibitors.10–12 We
additionally evaluated the association between depth of response
and survival outcomes within these prognostic subgroups.
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METHODS
Analysis population
The data were pooled from the BRIM-2, BRIM-3, BRIM-7 and
coBRIM studies. Detailed methods have been previously
reported.1,2,5,6 Briefly, BRIM-2 (ClinicalTrials.gov ID, NCT00949702)
was an open-label, multicentre phase 2 trial of oral vemurafenib.2
BRIM-3 (ClinicalTrials.gov ID: NCT01006980) was an open-label,
multicentre, randomised phase 3 trial of oral vemurafenib versus
intravenous dacarbazine.1,13 BRIM-7 (ClinicalTrials.gov ID:
NCT01271803) was an open-label, multicentre phase 1b dose-
escalation study of oral cobimetinib plus oral vemurafenib at
various doses.6 coBRIM (ClinicalTrials.gov ID, NCT01689519) was a
randomised, double-blind phase 3 study of oral cobimetinib plus
oral vemurafenib compared with placebo and vemurafenib.5,14
Key eligibility criteria were similar across trials, including age ≥ 18
years, unresectable stage IIIC or IV BRAFV600-mutated melanoma,
Eastern Cooperative Oncology Group performance status (ECOG
PS) of 0–1, and adequate organ function. BRIM-3 and coBRIM
enrolled previously untreated patients only, whereas BRIM-2
enrolled patients who had received prior systemic treatment for
advanced disease. Only BRAF inhibitor–naive patients from BRIM-7
were included in this analysis. All four trials allowed enrolment of
patients with previously treated, stable brain metastases. All
analysed patients received vemurafenib 960 mg orally twice daily
with or without cobimetinib 60 mg orally daily for 21 days
followed by a 7-day break.
Each trial was conducted in accordance with the Declaration of
Helsinki and the principles of Good Clinical and Laboratory
Practice and with the approval of appropriate ethics committees.
Ethical approval of the clinical studies included in this analysis
were provided by the local Institutional Review Boards (IRBs), and
a list of IRBs approving each study is documented in the
online Supplementary IRB List. All participants provided written
informed consent.
Depth of response
Depth of response was defined by maximal tumour reduction or
time to maximal tumour reduction. Tumour reduction (Max%SLD)
is defined as the greatest reduction or minimum increase in the
sum of longest diameters of the target lesion (SLD) from baseline
to the first progression of disease (PD) or date of last follow-up.
Max%SLD is calculated as ([smallest SLD measured before the first
PD–baseline SLD]/baseline SLD) × 100. Time to maximal change in
tumour size (TimeMax%SLD) is defined as the time from the start
of study treatment or randomisation to the date of reaching the
maximum change in SLD before or at the first PD. To demonstrate
the relationship with tumour reduction across the continuum of
response, from complete response (CR) to PD, each cohort was
rank-ordered for Max%SLD and divided into quartiles for
Kaplan–Meier analysis of survival outcomes.
Gene expression signatures
Gene expression signatures associated with PFS were previously
identified using archival formalin-fixed, paraffin-embedded
tumour samples from patients in the BRIM-2, BRIM-3, BRIM-7
and coBRIM trials (see Supplementary Data for the full list of genes
in each signature).10 Patients’ gene expression data, measured
using the nCOUNTER platform (NanoString Technologies, Seattle,
WA), were analysed in relation to depth of response variables by
Cox proportional-hazards modelling.
Statistical analysis
The primary end points for this analysis were PFS and OS,
estimated using the Kaplan–Meier method. The association of
depth of response with PFS and OS outcomes was tested by
multivariate Cox proportional-hazards modelling adjusted for
clinically relevant covariates (age, sex, race, geographic region,
ECOG PS, lactate dehydrogenase levels, disease stage, presence/
absence of liver metastasis, SLD of target lesions, Max%SLD and
TimeMax%SLD). Max%SLD and TimeMax%SLD were analysed as
continuous covariates in the proportional-hazards model, with
units of difference of 1% and 1 month, respectively. Time-
dependent multivariate Cox proportional-hazards modelling was
conducted as a sensitivity analysis.
All analyses were conducted using data cut-off dates of 1
February 2012 for BRIM-2; 8 July 2015 for BRIM-3; 2 December
2015 for BRIM-7 and 28 August 2015 for coBRIM, except for the
Kaplan–Meier analysis of survival outcomes and landmark
survival rates by tumour reduction quartiles, for which the data
cut-off dates of 10 July 2017 (BRIM-7) and 13 October 2017
(coBRIM) were used. All eligible patients, as defined by each
study protocol, were included in the analysis regardless of
treatment assignment.
Table 1. Cox proportional-hazards analysis of survival outcomes with
depth-of-response variables in pooled patient cohorts
Survival outcome Pooled V
cohort, n= 717
Pooled C+ V
cohort, n= 310
PFS
Event, n 609 203
K–M median, months (95% CI) 6.9 (6.2–7.0) 12.7 (10.6–14.7)
HR (95% CI)a 1.0 (reference) 0.80 (0.67–0.95)
p-valuea 0.0103
Max%SLD before/at first PD
HR per 1% increase in Max%SLD
(95% CI)b
1.01
(1.01–1.01)
1.02 (1.01–1.02)
p-valueb <0.0001 <0.0001
TimeMax%SLD before/at first PD
HR per 1 month increase in
TimeMax%SLD (95% CI)b
0.86
(0.84–0.88)
0.84 (0.81–0.87)
p-valueb <0.0001 <0.0001
OS
Event, n 495 148
K–M median, months (95% CI) 15.0
(13.8–16.8)
28.0 (21.8–31.2)
HR (95% CI)a 1.0 (reference) 0.84 (0.68–1.03)
p-valuea 0.0909
Max%SLD before/at first PD
HR per 1% increase in Max%SLD
(95% CI)b
1.01
(1.00–1.01)
1.01 (1.00–1.01)
p-valueb 0.0003 0.0071
TimeMax%SLD before/on first PD
HR per 1 month increase in
TimeMax%SLD (95% CI)b
0.88
(0.85–0.91)
0.85 (0.81, 0.89)
p-valueb <0.0001 <0.0001
C+ V cobimetinib plus vemurafenib, CI confidence interval, HR hazard
ratio, K–M Kaplan–Meier, Max%SLD maximum percentage change in the
sum of longest diameters, OS overall survival, PD disease progression, PFS
progression-free survival, SLD sum of longest diameters, TimeMax%SLD
time to maximum percentage change in the sum of longest diameters, V
vemurafenib monotherapy
aThe HR and p-values from the Cox proportional hazards regression model
are for the comparison of two-pooled cohorts (pooled cobimetinib plus
vemurafenib versus pooled vemurafenib)
bThe HR and p-values from the Cox proportional hazards regression model
are for Max%SLD of target lesions before or on the first PD, or TimeMax%
SLD of target lesion before or at the first PD within each cohort, analysed
as continuous variables within each cohort
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RESULTS
Patient demographics
Baseline characteristics were similar between the vemurafenib
monotherapy pooled cohort and the cobimetinib plus vemur-
afenib pooled cohort (Table S1). In both cohorts, ~45% of patients
had elevated lactate dehydrogenase (LDH) levels, a marker of poor
prognostic outcomes.15 Approximately one-third had liver metas-
tases at baseline. The median baseline lesion size (sum of longest
diameters) was 68 mm for the vemurafenib monotherapy pooled
cohort, and 63mm for the cobimetinib plus vemurafenib pooled
cohort.
Depth of response correlation to survival outcomes
Maximal tumour reduction and time to best response were
significantly associated with PFS and OS when evaluated as
continuous variables (Table 1). For every 1% increase in maximal
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Fig. 1 Waterfall plots of tumour reduction and time to best response in (a) vemurafenib monotherapy cohort and (b) cobimetinib plus
vemurafenib pooled cohort, and (c) Kaplan–Meier median time to best response in patients who had a response to treatment. Bars are colour-
coded to indicate whether time to best response is longer (red) or shorter (green) than the median. Dashed lines indicate the tumour
reduction ranges for the quartiles used in the analyses. C+ V cobimetinib plus vemurafenib, K–M Kaplan–Meier, Max%SLD maximum
percentage change in the sum of longest diameters, PD progression of disease, Q quartile, TimeMax%SLD time to maximum percentage
change in the sum of longest diameters, V vemurafenib
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tumour reduction within each cohort, there was an incremental
1–2% decrease in the relative risk of death or progression for
vemurafenib monotherapy and cobimetinib plus vemurafenib,
respectively, which was statistically significant (Table 1). For every
month increase in time to maximal response, the relative risk of
progression was decreased by 14% or 16%, and the relative risk of
death was decreased by 12% or 15% for vemurafenib mono-
therapy and cobimetinib plus vemurafenib, respectively (p < 0.001
for all; Table 1). Sensitivity analyses with time-dependent multi-
variate Cox proportional-hazards regression modelling confirmed
the independent association of tumour reduction with survival
outcomes. For time to best response, time-dependent Cox
modelling confirmed an association with OS but not with PFS
(Table S2). Similar findings were observed with the analysis
conducted in the subgroup of patients with gene signature
profiles and adjusted for signature profile (Table S3).
Maximal tumour reduction and time to best response were
greater in the cobimetinib plus vemurafenib pooled cohort
(Fig. 1a–c). In the vemurafenib monotherapy pooled cohort
(Fig. 1a), 91.9% patients experienced tumour reduction, with a
median reduction of −53.3%. In the cobimetinib plus vemurafenib
pooled cohort (Fig. 1b), a slightly greater proportion of patients
(95.9%) experienced tumour reduction, and the median reduction
was greater (−74.4%). Across treatment cohorts, patients with
deep responses (Q1; Fig. 1a, b) generally had a time to maximal
response greater than the median: 5.1 and 7.4 months for the
vemurafenib and cobimetinib plus vemurafenib cohorts, respec-
tively (Fig. 1c). This observation was particularly true for the
vemurafenib cohort. Thus, patients with a greater degree of
tumour reduction (Q1/Q2) appeared more likely to have a time to
best response that was longer than the median (Fig. 1a, b), while
patients with little or no tumour reduction typically had a time to
best response that was shorter than the median.
When grouped into quartiles based on tumour reduction
(Fig. 1a, b), patients with the deepest responses (Q1 in each
cohort) had better survival outcomes than those in Q2–Q4.
Median PFS in Q1 of the vemurafenib monotherapy pooled cohort
was 13.9 months (95% confidence interval [CI]: 11.1–17.8 months);
median OS was 32.1 months (95% CI: 25.9–42.5 months) (Fig. 2a,
b). Median PFS and OS for patients in Q1 of the cobimetinib plus
vemurafenib pooled cohort were not reached at the time of
analysis (Fig. 2c, d). The majority of patients within Q1 of the
cobimetinib plus vemurafenib pooled cohort experienced a CR
(67%, n= 49/73), whereas in Q1 of the vemurafenib monotherapy
cohort, fewer patients experienced a CR (35%, n= 60/171),
although the relationship between survival and depth of response
was maintained across cohorts. Further analysis of relationship to
landmark PFS and OS rates, which standardised quartiles across
treatment cohorts to control for the differences in distribution of
maximal tumour reduction and quartile ranges between the
treatment cohorts, found better survival outcomes in the
cobimetinib plus vemurafenib pooled cohort than in the
vemurafenib monotherapy pooled cohort across all Max%SLD
quartiles, regardless of the quartile definitions used (Fig. S1a–d).
Depth of response in relation to prognostic factors
Subgroups of patients with BRAF-mutated melanoma treated
with BRAF and MEK inhibitors are associated with distinct
survival outcomes, based on clinical characteristics (LDH levels,
ECOG PS, presence of liver metastasis and tumour size
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Fig. 2 Kaplan–Meier analysis of (a) PFS and (b) OS by tumour reduction quartiles, and in patients with complete response or disease
progression, in the vemurafenib monotherapy cohort, and of (c) PFS and (d) OS in the cobimetinib plus vemurafenib cohort. CI confidence
interval, CR complete response, C+ V cobimetinib plus vemurafenib, NE not estimable, OS overall survival, PD progression of disease, PFS
progression-free survival, Q quartile, V vemurafenib
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[SLD]).11,12 When patients in the pooled treatment cohorts were
sorted into these prognostic subgroups, we found greater
median tumour reduction in subgroups associated with good
prognosis and lesser median tumour reduction in subgroups
associated with poor prognosis (Table 2). In the cohort of
patients treated with cobimetinib plus vemurafenib, treatment
effect as assessed by maximal tumour reduction was less
influenced by poor prognostic factors than in the vemurafenib
monotherapy cohort.
In patients with BRAF-mutated metastatic melanoma treated
with BRAF and MEK inhibitors, certain gene signatures have been
identified as prognostic (Table S4)10,16—the ‘immune’ gene
signature being favourable and the ‘cell cycle’ being unfavourable.
Among patients with gene signature data, those in the
cobimetinib plus vemurafenib pooled cohort had a greater
maximal tumour reduction, objective response rate, CR rate and
a longer duration of response than those in the vemurafenib
monotherapy pooled cohort, regardless of gene signature type
(Table 3). This difference was more marked in patients expressing
the cell cycle gene signature in their tumours at baseline than in
patients expressing the immune gene signature.
DISCUSSION
In this exploratory analysis, greater tumour reduction was
consistently and independently associated with improved survival
outcomes when other known prognostic variables were taken into
account. These data suggest that while initial responses occur
quickly, deep responses are associated with longer time on
treatment and continue to develop over time. Association of time
to maximal response with survival outcomes was less consistent,
likely due to inherent bias. Cobimetinib plus vemurafenib
improved survival outcomes versus vemurafenib monotherapy
across maximal tumour reduction quartiles and clinical prognostic
subgroups. Patients with the deepest responses experienced a
long-term benefit from combined cobimetinib and vemurafenib
with 3-year landmark survival outcome rates comparable with
long-term survival reported with immunotherapies.17 Depth of
response has been associated with survival outcomes in other
solid tumour settings,8,9,18 and, in combination with these data,
suggests that depth of response is a meaningful indicator of
therapeutic activity and could identify patients with the best
chance of long-term survival. A previous analysis that included a
subset of patients from the current analyses (i.e., patients enrolled
Table 2. Tumour reduction in PFS prognostic subgroups in the vemurafenib monotherapy pooled cohort and the cobimetinib plus vemurafenib
pooled cohort
Prognostic subgroup Max%SLD in pooled V cohort Max%SLD in pooled C+ V cohort
n Median IQR n Median IQR
All pooled patients with tumour reductiona 627 –53.3 –73.6 to –33.8 282 –74.4 –94.1 to –55.2
LDH level normal and liver metastases absent 266 –56.8 –88.6 to –38.2 117 –75.0 –100 to –56.3
LDH level normal and liver metastases present 87 –61.1 –77.2 to –43.4 35 –75.0 –90.4 to –51.7
LDH level elevated and ECOG PS= 0 121 –47.5 –69.1 to –30.3 85 –77.0 –91.0 to –61.8
LDH elevated and ECOG PS > 0 148 –45.7 –59.9 to –27.7 39 –60.0 –75.4 to –46.2
C+ V cobimetinib plus vemurafenib, ECOG PS Eastern Cooperative Oncology Group performance status, IQR interquartile range, LDH lactate dehydrogenase,
Max%SLD maximum percentage change in the sum of longest diameters, V vemurafenib monotherapy
aIncludes only patients with negative Max%SLD of target lesion
Table 3. Objective responses by pooled cohort for all patients with gene expression signature data
Variable Patients with immune gene signature Patients with cell cycle gene signature
Pooled V cohort
(n= 148)
Pooled C+ V cohort
(n= 72)
Pooled V cohort
(n= 172)
Pooled C+ V cohort
(n= 71)
Responders, n 97 54 77 52
Response rate, % (95% CI)
CR 16.2 (10.7, 23.2) 19.4 (11.1, 30.5) 5.2 (2.4, 9.7) 14.1 (7.0, 24.4)
PR 49.3 (41.0, 57.7) 55.6 (43.4, 67.3) 39.5 (32.2, 47.3) 59.2 (46.8, 70.7)
SD 23.0 (16.5, 30.6) 13.9 (6.9, 24.1) 38.4 (31.1, 46.1) 18.3 (10.1, 29.3)
PD 8.1 (4.3, 13.7) 8.3 (3.1, 17.3) 12.2 (7.7, 18.1) 7.0 (2.3, 15.7)
Median Max%SLD (IQR) −55.6 (−81.6, −33.3) −66.1 (−89.5, −45.5) −44.8 (−63.7, −20.0) −72.4 (−91.0, −51.9)
Median duration of response, months
(95% CI)
7.6 (5.8, 13.2) 13.5 (9.5, NE) 7.1 (5.7, 8.3) 11.7 (9.3, 19.8)
HR (95% CI)a 0.48 (0.31, 0.76) 0.53 (0.33, 0.84)
p-valuea 0.0014 0.0074
C+ V cobimetinib plus vemurafenib, CI confidence interval, CR complete response, ECOG PS Eastern Cooperative Oncology Group performance status, HR
hazard ratio, IQR interquartile range, LDH lactate dehydrogenase, Max%SLD maximum percentage change in the sum of longest diameters, NE not estimable,
PD progression of disease, PR partial response, SD stable disease, V vemurafenib monotherapy
aCox proportional-hazards regression model with pooled cohort adjusting for age, sex, race, geographic region, ECOG PS, LDH, disease stage, liver metastases,
sum of longest diameters of target lesion. The HR and p-values are for the comparison of the pooled cobimetinib plus vemurafenib cohort versus the pooled
vemurafenib monotherapy cohort
Impact of depth of response on survival in patients treated with. . .
KD. Lewis et al.
526
in the BRIM-2 and BRIM-3 studies) found no correlation between
early response at 12 weeks and OS in patients with melanoma
treated with vemurafenib or dacarbazine.19 However, it is
important to note that the results of this analysis would have
been confounded by the use of a defined time point, creating
heterogeneous groups of patients within each response group. In
the current analysis, median time to maximal tumour reduction
was 5.1 and 7.4 months with vemurafenib and with cobimetinib
plus vemurafenib, respectively; thus, while some patients may
have already achieved maximal response at 12 weeks, a
substantial proportion would be expected to have continued
tumour shrinkage beyond this time point. In the current analysis,
we evaluated depth of response as a continuous variable (maximal
tumour reduction or time to maximal response), thereby
minimising heterogeneity and reducing confounding.
Depth of response, particularly maximal tumour reduction,
appears to provide additional prognostic/predictive information
beyond that obtained from traditional clinical variables (such as
elevated LDH levels and measures of tumour burden), or
baseline tumour gene expression signature. These can be
assessed prior to the initiation of therapy and used to counsel
patients about their expected outcomes. Depth of response
appears to refine prognostication once response assessments
are performed. Gene expression signature has independent
prognostic significance for survival outcomes when incorpo-
rated into recursive partition models using clinical variables.16
The qualitative differences in maximal tumour reduction
observed between the immune and cell cycle gene signatures
may explain equalisation of maximal tumour reduction across
clinical prognostic groups in the cobimetinib plus vemurafenib
cohort versus the vemurafenib cohort, given the higher
prevalence of the ‘cell cycle’ gene signature in unfavourable
clinical prognostic groups.16
The strengths of this exploratory analysis include a large patient
sample with sufficient survival follow-up for robust statistical analysis
across prognostic subgroups, including gene signatures, made
possible by pooling patients across a series of studies with similar
populations. Limitations include the comparison having been carried
out post-randomisation, so that potentially important prognostic
values are not balanced between quartiles, the influence of
immortal time bias associated with time-dependent outcomes,
and the OS end point potentially being confounded by post-
progression treatments. Sensitivity analyses of time-dependent Cox
proportional-hazards regression modelling were performed to
address the potential confounding factor of immortal time bias in
this type of analysis,20 which confirmed the independent association
of tumour reduction with survival outcomes.
In conclusion, depth of response particularly as measured by
maximal tumour reduction is associated with survival outcomes,
independent of gene signatures or other clinical prognostic
factors. Depth of response may provide prognostic/predictive
value in addition to traditional clinical prognostic variables, and
merits further evaluation in integrated prognostic/predictive
models based on this analysis as well as other reported analyses.
Incorporation of on-treatment data could further refine prognostic
models that may help with individual treatment decisions. In this
exploratory analysis, cobimetinib plus vemurafenib improved
outcomes across response quartiles regardless of clinical prog-
nostic factors or gene signatures and provided durable survival
benefits in patients with the deepest responses. These findings
provide further support for combination BRAF and MEK inhibition
as a standard of care in this disease setting.
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